Cargando…

Hyperhaploid karyotypes in multiple myeloma

Detalles Bibliográficos
Autores principales:	Sawyer, Jeffrey R., Morgan, Gareth J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5667958/ https://www.ncbi.nlm.nih.gov/pubmed/29108224 http://dx.doi.org/10.18632/oncotarget.20875

Ejemplares similares

Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of TP53
por: Ashby, Cody, et al.
Publicado: (2019)

Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations
por: Peterson, Jess F., et al.
Publicado: (2019)

The genomic features associated with high-risk multiple myeloma
por: Walker, Brian A., et al.
Publicado: (2018)

Conventional Karyotyping and Fluorescence In Situ Hybridization for Detection of Chromosomal Abnormalities in Multiple Myeloma
por: Crabtree, Matthew, et al.
Publicado: (2022)

The Utilization of Karyotyping, iFISH, and MLPA for the Detection of Recurrence Genetic Aberrations in Multiple Myeloma
por: Sommaluan, Suchada, et al.
Publicado: (2017)

Identification of the true hyperdiploid multiple myeloma subset by combining conventional karyotyping and FISH analysis
por: Barilà, Gregorio, et al.
Publicado: (2020)

Immunotherapy for Multiple Myeloma
por: Kröger, Nicolaus, et al.
Publicado: (2012)

NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial
por: Rosa-Rosa, Juan Manuel, et al.
Publicado: (2022)

Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006)

Novel therapies for multiple myeloma
por: Wallington-Beddoe, Craig T., et al.
Publicado: (2017)

Latest Development in Multiple Myeloma
por: Imai, Yoichi
Publicado: (2020)

Introduction to “Immunotherapies for Multiple Myeloma”
por: Offidani, Massimo, et al.
Publicado: (2020)

Immunomodulatory Agents for Multiple Myeloma
por: Minařík, Jiří, et al.
Publicado: (2022)

Pros and Cons for Fluorescent in Situ Hybridization, Karyotyping and Next Generation Sequencing for Diagnosis and Follow-up of Multiple Myeloma
por: Ikbal Atli, E, et al.
Publicado: (2021)

Cancer drug resistance in multiple myeloma
por: Uckun, Fatih M.
Publicado: (2022)

To be or not to be: the role of CD56 in multiple myeloma
por: Cottini, Francesca, et al.
Publicado: (2023)

Multiple mechanisms can disrupt oncogenic pathways in multiple myeloma
por: Hoang, Phuc H., et al.
Publicado: (2018)

Circulating tumour DNA analysis in multiple myeloma
por: Mithraprabhu, Sridurga, et al.
Publicado: (2017)

Lenalidomide in the Treatment of Lymphoproliferative Disorders and Multiple Myeloma
por: Liberati, Anna Marina, et al.
Publicado: (2013)

Methods for reducing delays in the diagnosis of multiple myeloma
por: Koshiaris, Constantinos
Publicado: (2019)

Recent Advances on the Pathobiology and Treatment of Multiple Myeloma
por: Amodio, Nicola
Publicado: (2021)

Immunotherapy for multiple myeloma: new chances and hope
por: Xu, Jingyu, et al.
Publicado: (2023)

Near tetrapoloid karyotype with translocation t(11;14) in a Moroccan patient with amyloid light-chain amyloidosis and multiple myeloma
por: Hamdaoui, Hasna, et al.
Publicado: (2020)

The hope for targeting fatty acid binding proteins in multiple myeloma
por: Fairfield, Heather, et al.
Publicado: (2023)

MRD in multiple myeloma: more questions than answers?
por: Moreau, Philippe, et al.
Publicado: (2017)

Optimizing therapy for del(17p) multiple myeloma
por: Avet-Loiseau, Hervé, et al.
Publicado: (2017)

The Road to a Cure: Emerging Treatments for Multiple Myeloma
por: Caers, Jo
Publicado: (2020)

MRD negativity: considerations for older adults with multiple myeloma
por: Mian, Hira, et al.
Publicado: (2023)

An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome
por: Sawyer, Jeffrey R., et al.
Publicado: (2019)

Trogocytosis represents a novel mechanism of action of daratumumab in multiple myeloma
por: Krejcik, Jakub, et al.
Publicado: (2018)

Prognostic impact of Ikaros expression in lenalidomide-treated multiple myeloma
por: Krönke, Jan, et al.
Publicado: (2017)

Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma
por: Zhou, Jianbiao, et al.
Publicado: (2019)

Imaging in multiple myeloma: Computed tomography or magnetic resonance imaging?
por: Tagliafico, Alberto Stefano
Publicado: (2021)

Proptosis with hemiplegia: Unusual presentation of multiple myeloma
por: Ghosh, K
Publicado: (2018)

RNA processing: a new player of genomic instability in multiple myeloma
por: Marchesini, Matteo, et al.
Publicado: (2017)

The evolving role and utility of off-label drug use in multiple myeloma
por: Stoeckle, James H, et al.
Publicado: (2021)

New Perspectives Offered by Nuclear Medicine for the Imaging and Therapy of Multiple Myeloma
por: Mesguich, Charles, et al.
Publicado: (2016)

CAR T-cell treatment of high-risk multiple myeloma: will there be a cure?
por: Gahrton, Gösta
Publicado: (2023)

The cellular architecture of multiple myeloma
por: Vicente-Dueñas, Carolina, et al.
Publicado: (2012)

Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma
por: Tschautscher, Marcella A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_msm8kiv91rp8u1h36pbsoqc8se